Success Metrics

Completion Rate
0%(0/2)
Active Trials
0(0%)
Terminated
2(67%)

Phase Distribution

Ph not_applicable
1
33%

Phase Distribution

0

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution1 total trials
N/ANon-phased studies
1(100.0%)

Highest Phase Reached

Unknown

Trial Status & Enrollment

Completion Rate

0.0%

0 of 2 finished

Non-Completion Rate

100.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Active(1)
Terminated(2)

Detailed Status

Terminated2
Enrolling by invitation1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
0.0%
Most Advanced
N/A

Trials by Phase

N/A1 (100.0%)

Trials by Status

enrolling_by_invitation133%
terminated267%

Recent Activity

0 active trials
Showing 3 of 3
terminated

Real-World Experience - Barostim™ Advancing the Level of Clinical Evidence (REBALANCE Registry)

NCT04502316
enrolling_by_invitationnot_applicable

Barostim-Enabled NEurohormonal Intervention For Improving Treatment of Heart Failure

NCT07232030
terminated

Symptomatic CRT Patients: Real-World Experience - Barostim™ Advancing the Level of Clinical Evidence

NCT05860348

Clinical Trials (3)

Showing 3 of 3 trials
NCT04502316

Real-World Experience - Barostim™ Advancing the Level of Clinical Evidence (REBALANCE Registry)

Terminated
NCT07232030Not Applicable

Barostim-Enabled NEurohormonal Intervention For Improving Treatment of Heart Failure

Enrolling By Invitation
NCT05860348

Symptomatic CRT Patients: Real-World Experience - Barostim™ Advancing the Level of Clinical Evidence

Terminated

All 3 trials loaded

Drug Details

Intervention Type
DEVICE
Total Trials
3